top of page


Next Gen Immuno-Oncology Products
Using our broadly versatile SnAP technology both of our programs combine clinically validated pieces in a unique way to create a ‘whole greater than the sum of its parts’ … for truly targeted delivery of immune system function and, hence, tumor killing.
MDT101 "MeKine"
The proven power of cytokines combined with high tumor specificity of antibodies:
-
"Masked"/deactivated cytokine (IL-2)
-
Fused to antibody via protease cleavable linkers
Resulting in:
-
Potent and specific tumor cell killing
-
Improved therapeutic window

MDT201 "MeCAR"
A single T-cell construct (allogenic or autologous) for use against multiple tumor types. Tumor-targeting antibody dosed separately for unparalleled control:
-
T-cell fused to meditope peptide
-
Tumor-targeting antibody/antibodies dosed separately
Resulting in:
-
Unparalleled specificity and control of T-cell activation and potency
-
Reduced development time and manufacturing cost

bottom of page